drugset / Trial / NCT01968317

Megestrol Acetate Plus Metformin to Megestrol Acetate in Patients With Endometrial Atypical Hyperplasia or Early Stage Endometrial Adenocarcinoma

NCT01968317

RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to see if megestrol acetate plus metformin will be more effective in returning the endometrial tissue to a normal state than megestrol acetate alone in patients with endometrial atypical hyperplasia or early stage endometrial adenocarcinoma.

Timeline

Start
2013-10
Primary completion
2017-10
Completion
2017-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Megestrol Acetate Other / unclassified 160 mg Oral
Subject Metformin Small molecule 500 mg Oral